行情

TOVX

TOVX

THERIVA BIOLOGICS INC
AMEX
0.6700
-0.0300
-4.29%
已收盘, 16:00 12/06 EST
开盘
0.6900
昨收
0.7000
最高
0.7099
最低
0.6700
成交量
7.07万
成交额
1.59万
52周最高
4.394
52周最低
0.5750
市值
1,061.55万
市盈率(TTM)
-0.4967
分时
5日
1月
3月
1年
5年
Synthetic Biologics 获得委员会批准在细胞移植受体中推进 SYN-004 试验;股价上涨
Synthetic Biologics 获得委员会批准在细胞移植受体中推进 SYN-004 试验;股价上涨
MT Newswires · 09/27 11:54
TOVX 简况
Theriva Biologics, Inc., formerly Synthetic Biologics, Inc., is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of unmet need. The Company is engaged in the development of oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a sustained anti-tumor response by the patient's immune system. Its lead candidates are: VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier; SYN-004 (ribaxamase) which is designed to degrade IV beta-lactam antibiotics within the gastrointestinal (GI) tract, and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under current good manufacturing practice (cGMP) conditions and intended to treat both local GI and systemic diseases.

微牛提供Theriva Biologics Inc(AMEX-TOVX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的TOVX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易TOVX股票基本功能。